Galidesivir

Generic Name: Galidesivir

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₁₁H_₁₅N_₅O_₃

CAS Number: 249503-25-1

Unique Ingredient Identifier: OLF97F86A7

Background: Galidesivir is an adenosine analogue that has been investigated for use against Zaire Ebolavirus. In animal studies, galidesivir was effective in increasing the survival rates from infections caused by various pathogens, including Ebola, Marburg, Yellow Fever and Zika viruses. In vitro, it displayed broad-spectrum antiviral activity against various negative- and positive-sense RNA viruses, including coronaviruses, filoviruses, and arenaviruses. Phase 1 clinical trials have begun to determine the safety of this drug in humans. Because of its activity against other coronaviruses, it may be studied as a potential therapy for COVID-19.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Everything you need to know about candidate vaccines and treatments for Marburg disease

Rwanda faces a Marburg disease outbreak with 49 infected and 12 deaths. WHO assesses risk as very high, with potential spread to neighboring countries. No licensed vaccines or treatments exist, but human trials for experimental vaccines and therapeutics are imminent. 28 vaccine candidates are in development, with four prioritized by WHO. The Sabin Vaccine Institute's adenovirus-based vaccine is most advanced, with 700 doses shipped to Rwanda. WHO also organizes the SOLIDARITY PARTNERS trial to evaluate treatments like remdesivir and MBP091. Rwanda's Ministry of Health urges public vigilance and hygiene.

Related Clinical Trials:

Monovalent Chimpanzee Adenoviral-Vectored Marburg Virus Vaccine in Healthy Adults

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy